Regulus Therapeutics Valuation
| RGLS Stock | USD 1.28 0.01 0.79% |
Today, the company appears to be undervalued. Regulus Therapeutics holds a recent Real Value of $3.51 per share. The prevailing price of the company is $1.28. Our model determines the value of Regulus Therapeutics from analyzing the company fundamentals such as Return On Equity of -0.72, shares outstanding of 65.5 M, and Shares Owned By Institutions of 88.28 % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Regulus Therapeutics' valuation include:
Price Book 0.9584 | Enterprise Value | Enterprise Value Ebitda 0.5691 | Price Sales 7.4299 | Enterprise Value Revenue 0.6573 |
Undervalued
Today
Please note that Regulus Therapeutics' price fluctuation is unstable at this time. Calculation of the real value of Regulus Therapeutics is based on 3 months time horizon. Increasing Regulus Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Regulus stock is determined by what a typical buyer is willing to pay for full or partial control of Regulus Therapeutics. Since Regulus Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Regulus Stock. However, Regulus Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.28 | Real 3.51 | Target 10.33 | Hype 1.28 |
The intrinsic value of Regulus Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Regulus Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Regulus Therapeutics helps investors to forecast how Regulus stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Regulus Therapeutics more accurately as focusing exclusively on Regulus Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Regulus Therapeutics' intrinsic value based on its ongoing forecasts of Regulus Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Regulus Therapeutics' closest peers.
Regulus Therapeutics Cash |
|
Regulus Valuation Trend
Regulus Therapeutics' real value is important for investors to make better decisions and a more accurate overall view of Regulus Therapeutics' financial worth over time. Using both Regulus Therapeutics' enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
Regulus Therapeutics Total Value Analysis
Regulus Therapeutics is at this time expected to have valuation of (3.64 M) with market capitalization of 83.84 M, debt of 2.39 M, and cash on hands of 47.53 M. The negative valuation of Regulus Therapeutics may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Regulus Therapeutics fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(3.64 M) | 83.84 M | 2.39 M | 47.53 M |
Regulus Therapeutics Asset Utilization
One of the ways to look at asset utilization of Regulus is to check how much profit was generated for every dollar of assets it reports. Regulus Therapeutics holds a negative application of assets of -0.42 pct., losing $0.004239 for each dollar of assets held by the company. Inadequate asset utilization implies the company is being less effective with each dollar of assets it holds. Put it differently, asset utilization of Regulus Therapeutics shows how discouraging it operates for each dollar spent on its assets.Regulus Therapeutics Ownership Allocation
Regulus Therapeutics owns a total of 65.5 Million outstanding shares. The majority of Regulus Therapeutics outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Regulus Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Regulus Therapeutics. Please pay attention to any change in the institutional holdings of Regulus Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.Regulus Therapeutics Profitability Analysis
Net Loss for the year was (30.04 M) with loss before overhead, payroll, taxes, and interest of (22.62 M).About Regulus Therapeutics Valuation
The stock valuation mechanism determines Regulus Therapeutics' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Regulus Therapeutics based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Regulus Therapeutics. We calculate exposure to Regulus Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Regulus Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -19 M | -18.1 M | |
| Pretax Profit Margin | (1.81) | (1.90) | |
| Operating Profit Margin | (1.63) | (1.71) | |
| Net Loss | (1.75) | (1.84) | |
| Gross Profit Margin | 1.15 | 1.21 |
Regulus Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Regulus Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 19 M |
Regulus Therapeutics Current Valuation Indicators
Regulus Therapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Regulus Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Regulus Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Regulus Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Regulus Therapeutics' worth.Additional Tools for Regulus Stock Analysis
When running Regulus Therapeutics' price analysis, check to measure Regulus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regulus Therapeutics is operating at the current time. Most of Regulus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Regulus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regulus Therapeutics' price. Additionally, you may evaluate how the addition of Regulus Therapeutics to your portfolios can decrease your overall portfolio volatility.